Sanofi has long been at the forefront of the drive to find new, innovative solutions for patients in different therapeutic areas, such as diabetes, cancer, cardiovascular diseases or rare diseases. Marc-Antoine Lucchini, SVP Diabetes and Cardiovascular Europe and Coordinator, Sanofi Europe, discusses some of the company’s achievements…
What would you say have been the most significant developments in the pharmaceutical industry over the past 21 years?
The most significant development has been the move from chemistry-based medicine to biologics, which brings a greater focus on precision medicine. Driven by advances in genomics, pharmaceuticals, technology and eHealth, we are moving from a world in which medicine was used to treat symptoms, to a world that enables healthcare professionals to intervene much earlier in the disease process. This brings the hope of altering it one day.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
2017 has been a year of evolution for Sanofi’s diabetes and cardiovascular businesses in response to a challenging environment. We are expanding our novel approach to R&D, helping deliver improved patient outcomes through value-based medicines (sotagliflozin) and integrated care solutions, while renewing our thinking to address ambitious long-term research goals (dual-agonist).
[insert_php] if ( zmember_valid_subscription() ) { echo ‘
DOWNLOAD THE ENTIRE 21st ANNIVERSARY SUPPLEMENT NOW
Our 21 @ 21 Anniversary Supplement is just one of the many resources a free subscription to European Pharmaceutical Review provides. If you are already a subscriber, login to download the PDF.
Not yet a subscriber? Join our growing community of thousands of industry professionals and gain access to:
Bi-monthly issues in print and/or digital format
Case studies, whitepapers, webinars and industry-leading content
Breaking news and features
Our extensive online archive of over 8,500 articles and past issues
Sanofi has long been at the forefront of the drive to find new, innovative solutions for patients in different therapeutic areas, such as diabetes, cancer, cardiovascular diseases or rare diseases. We have transformed our development activities since 2011, refocusing our pipeline and targeting areas where there is great unmet patient need – where we can make a real difference. In the past three years, we have launched several important products – Praluent being a prime example, that is helping to tackle cardiovascular disease. It is one of the first drugs to inhibit a protein called PCSK-9 which enables us to control cholesterol levels with unprecedented efficacy.
Looking ahead to the next few years, what do you think are likely to be the main opportunities and challenges affecting the industry?
In terms of opportunities, the technology and computing revolutions are going to greatly enhance the speed at which we study diseases, identify targets and develop new molecules. Furthermore, those advances will revolutionise the understanding of patients’ behaviours through the advent of connected devices, apps and an increased awareness from patients of their own health.
Patient engagement is also critical for us. We want to not only account better for patient needs for understanding the dayto- day reality of dealing with the disease, but also when designing clinical protocols. Today, a person with diabetes knows that managing the disease is tedious and timeconsuming. Diabetes management goes far beyond the treatment itself; it also includes taking extra care with food and exercise, monitoring blood sugar levels throughout the day, and taking time to prevent or manage common related health problems with eyes, feet, kidneys and the heart.
Utilising integrated care solutions is an avenue that Sanofi is exploring as it is Marc-Antoine Lucchini, SVP Diabetes and Cardiovascular Europe and Coordinator, Sanofi Europe key to providing ‘more than medicines’. By offering combinations of medicines, devices, software, support tools and analytics, patients are able to play a more engaged role in managing their diabetes outcomes. We also want to help payers optimise their expenditure on diabetes care.
With extensive in-house expertise, in collaboration with partners (such as Voluntis) and in our Onduo joint venture with Verily, we are taking a leading role in this exciting new area. This reflects our wider ambition to transform the management of diabetes with patientoriented, integrated care solutions. We are also applying this approach to other therapeutic areas where we work.
On the subject of challenges, I think we need to protect innovation by reinforcing the dialogue with different stakeholders at European and national level. In this way we can ensure healthcare systems and payers understand the value that is being created in new therapeutic solutions. Public health awareness and action is also a challenge and we need to use the full capacity of health care systems to increase our efforts in prevention and vaccination. How is your company preparing for these developments?
In addition to the relationships I have mentioned, Sanofi has strengthened its relationship with Evidation Health – the leader in quantifying health behaviours. For the next three years we will be working closely to better understand how the daily burden of disease affects patient outcomes. This is just one example of how valuable digital tools use data and analytics to gain real-world insights that help patients.
Additionally, Sanofi supports activities and initiatives from organisations such as the various global BioLabs. These spaces improve patient care by encouraging early-stage innovations and extending that information in a high throughput environment of drug development with the aim of delivering breakthrough therapies to patients.
What would you say has been Sanofi’s outstanding achievement (or achievements) of recent years, and what impact has this had on patients and potentially the industry in general?
Where a company like Sanofi can make a difference is by advancing science and translating it into medicines for patients, where no suitable treatment exists. In March 2017 we received approval from the FDA, followed in September by the EMA, for a ground-breaking new molecule in the treatment of atopic dermatitis – a highly debilitating skin disease. Dupixent is a bispecific antibody and so attacks two targets at once.
Successful innovations in pharma are likely to increasingly rely on partnerships and collaborations between manufacturers, suppliers, academics, and a whole range of other companies and organisations. What do you look for in these relationships, and can you give an example of one that has worked particularly well for Sanofi?
Sanofi R&D believes in partnering and external innovation. In recent years, it has become clear that our traditional scientific approaches, on which we have been relying for decades, will not be sufficient to create the next generation of medical breakthroughs.
Sanofi partnerships with leading academic institutions and innovative biotech companies have led to the discovery and development of groundbreaking new therapies that empower the lives of patients every day. We have a tremendous need to understand the complex biology of diseases. Gaining these insights requires an enormous amount of research whose success will rely on strong global collaborations, public-private partnerships and innovative initiatives within the private sector. While we do not comment on deals under negotiation, we can highlight a couple of the important partnerships from this year.
One such example is the major strategic collaboration in the immunology space, utilising a novel biologics platform to advance the research strategy through the development of transformative multi-targeting treatment approaches. We also have an agreement to develop a novel CD40L antibody with the potential to treat a broad range of autoimmune diseases. CD40L suppresses the activity of a cellular pathway that is overactive in many autoimmune diseases, including Lupus and Multiple Sclerosis. In the diabetes field, we are conducting an early-stage strategic investment-partnership focused on novel next-generation insulin analogues.
Sanofi profile
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, we transform scientific innovation into healthcare solutions in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes, cardiovascular and consumer healthcare. More than 100,000 employees are dedicated to making a difference to patients’ daily lives. Our presence spans 100 countries and we have industrial sites in more than 40 countries. In 2016 company sales were €33,821m.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.